Felix Preisser1, Marco Bandini2, Elio Mazzone2, Sebastiano Nazzani3, Michele Marchioni4, Zhe Tian5, Fred Saad5, Raisa S Pompe6, Shahrokh F Shariat7, Hans Heinzer8, Francesco Montorsi9, Hartwig Huland8, Markus Graefen8, Derya Tilki10, Pierre I Karakiewicz5. 1. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. Electronic address: felixpreisser@gmx.de. 2. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. 3. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Academic Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy. 4. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada; Department of Urology, SS Annunziata Hospital, "G.D'Annunzio" University of Chieti, Chieti, Italy. 5. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Quebec, Canada. 6. Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 7. Department of Urology, Medical University of Vienna, Vienna, Austria. 8. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 9. Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy. 10. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKROUND: Accurate life expectancy estimation is crucial in clinical decision-making including management and treatment of clinically localized prostate cancer (PCa). OBJECTIVE: We hypothesized that Social Security Administration (SSA) life tables' derived survival estimates closely follow observed survival of PCa patients. To test this relationship, we examined 10-yr overall survival rates in patients with clinically localized PCa and compared it with survival estimates derived from the SSA life tables. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004), we identified patients aged >50-<90yr. Follow-up was at least 10 yr for patients who did not die of disease or other causes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Monte Carlo method was used to define individual survival in years, according to the SSA life tables (2004-2014). Subsequently, SSA life tables' predicted survival was compared with observed survival rates in Kaplan-Meier analyses. Subgroup analyses were stratified according to treatment type and D'Amico risk classification. RESULTS AND LIMITATIONS: Overall, 39191 patients with localized PCa were identified. At 10-yr follow-up, the SSA life tables' predicted survival was 69.5% versus 73.1% according to the observed rate (p<0.0001). The largest differences between estimated versus observed survival rates were recorded for D'Amico low-risk PCa (8.0%), brachytherapy (9.1%), and radical prostatectomy (8.6%) patients. Conversely, the smallest differences were recorded for external beam radiotherapy (1.7%) and unknown treatment type (1.6%) patients. CONCLUSIONS: Overall, SSA life tables' predicted life expectancy closely approximate observed overall survival rates. However, SSA life tables' predicted rates underestimate by as much as 9.1% the survival in brachytherapy patients, as well as in D'Amico low-risk and radical prostatectomy patients. In these patient categories, an adjustment for the degree of underestimation might be required when counseling is provided in clinical practice. PATIENT SUMMARY: Social Security Administration (SSA) life tables' predicted life expectancy closely approximate observed overall survival rates. However, SSA life tables' predicted rates underestimate by as much as 9.1% the survival in brachytherapy patients, as well as in D'Amico low-risk and radical prostatectomy patients.
BACKROUND: Accurate life expectancy estimation is crucial in clinical decision-making including management and treatment of clinically localized prostate cancer (PCa). OBJECTIVE: We hypothesized that Social Security Administration (SSA) life tables' derived survival estimates closely follow observed survival of PCa patients. To test this relationship, we examined 10-yr overall survival rates in patients with clinically localized PCa and compared it with survival estimates derived from the SSA life tables. PATIENTS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2004), we identified patients aged >50-<90yr. Follow-up was at least 10 yr for patients who did not die of disease or other causes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Monte Carlo method was used to define individual survival in years, according to the SSA life tables (2004-2014). Subsequently, SSA life tables' predicted survival was compared with observed survival rates in Kaplan-Meier analyses. Subgroup analyses were stratified according to treatment type and D'Amico risk classification. RESULTS AND LIMITATIONS: Overall, 39191 patients with localized PCa were identified. At 10-yr follow-up, the SSA life tables' predicted survival was 69.5% versus 73.1% according to the observed rate (p<0.0001). The largest differences between estimated versus observed survival rates were recorded for D'Amico low-risk PCa (8.0%), brachytherapy (9.1%), and radical prostatectomy (8.6%) patients. Conversely, the smallest differences were recorded for external beam radiotherapy (1.7%) and unknown treatment type (1.6%) patients. CONCLUSIONS: Overall, SSA life tables' predicted life expectancy closely approximate observed overall survival rates. However, SSA life tables' predicted rates underestimate by as much as 9.1% the survival in brachytherapy patients, as well as in D'Amico low-risk and radical prostatectomy patients. In these patient categories, an adjustment for the degree of underestimation might be required when counseling is provided in clinical practice. PATIENT SUMMARY: Social Security Administration (SSA) life tables' predicted life expectancy closely approximate observed overall survival rates. However, SSA life tables' predicted rates underestimate by as much as 9.1% the survival in brachytherapy patients, as well as in D'Amico low-risk and radical prostatectomy patients.
Authors: Elio Mazzone; Sophie Knipper; Francesco A Mistretta; Zhe Tian; Carlotta Palumbo; Denis Soulieres; Ottavio De Cobelli; Francesco Montorsi; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2019-08-28 Impact factor: 4.226
Authors: Francesco Chierigo; Marco Borghesi; Christoph Würnschimmel; Rocco Simone Flammia; Benedikt Horlemann; Gabriele Sorce; Benedikt Hoeh; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Francesco Montorsi; Felix K H Chun; Shahrokh F Shariat; Guglielmo Mantica; Nazareno Suardi; Carlo Terrone; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2022-05-04 Impact factor: 2.370
Authors: Sophie Knipper; Cristina Dzyuba-Negrean; Carlotta Palumbo; Angela Pecoraro; Giuseppe Rosiello; Zhe Tian; Alberto Briganti; Fred Saad; Derya Tilki; Markus Graefen; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2019-09-21 Impact factor: 2.370
Authors: Felix Preisser; Elio Mazzone; Sophie Knipper; Sebastiano Nazzani; Marco Bandini; Shahrokh F Shariat; Michele Marchioni; Zhe Tian; Fred Saad; Daniel Taussky; Alberto Briganti; Hartwig Huland; Markus Graefen; Derya Tilki; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2019-11-29 Impact factor: 1.862